Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)

Dr. Aaron S. Rosenberg

Hematology Oncology | Hematology | Oncology
Regents Of The Univ Of Ca
3850 G St, 
Merced, CA 
Offers Telehealth
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Regents Of The Univ Of Ca
3850 G St, 
Merced, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Aaron Rosenberg is a Hematologist Oncology specialist and a Hematologist in Merced, California. Dr. Rosenberg is rated as an Advanced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Diffuse Large B-Cell Lymphoma (DLBCL).

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Oroville Hospital
University Of California Davis Medical Center
Enloe Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

REGENTS OF THE UNIV OF CA
3850 G St, Merced, CA 95340

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Other, Biological
Study Drug: Isatuximab
Study Phase: Phase 2
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drug: Belantamab Mafodotin
Study Phase: Phase 1
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 02, 2024
Intervention Type: Drug
Study Drugs: TAK-981, Mezagitamab, Daratumumab and Hyaluronidase-fihj
Study Phase: Phase 1/Phase 2
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Procedure, Drug
Study Drugs: Carfilzomib, Dexamethasone, Dexamethasone Sodium Phosphate, Lenalidomide, MDM2 Inhibitor KRT-232
Study Phase: Phase 1
View 5 Less Clinical Trials

48 Total Publications

Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data.
Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data.
Journal: Journal of managed care & specialty pharmacy
Published: July 24, 2025
Similar Doctors
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Haifaa Abdulhaq
Hematology Oncology | Hematology | Oncology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Haifaa Abdulhaq
Hematology Oncology | Hematology | Oncology

Community Health Partners

785 N Medical Ctr Dr W, Suite 203, 
Clovis, CA 
 (56.2 miles away)
559-387-1900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Haifaa Abdulhaq is a Hematologist Oncology specialist and a Hematologist in Clovis, California. Dr. Abdulhaq is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Her top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration.

Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Paul R. Kaesberg
Hematology Oncology | Oncology | Hematology
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Paul R. Kaesberg
Hematology Oncology | Oncology | Hematology

Regents Of The Univ Of Ca

3850 G St, 
Merced, CA 
 (0.1 miles away)
209-384-6528
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Kaesberg is a Hematologist Oncology specialist and an Oncologist in Merced, California. Dr. Kaesberg has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Aspiration.

Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Mehrad Abedi
Hematology Oncology | Oncology | Hematology
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Mehrad Abedi
Hematology Oncology | Oncology | Hematology

Regents Of The Univ Of Ca

3850 G St, 
Merced, CA 
 (0.1 miles away)
209-384-6528
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mehrad Abedi is a Hematologist Oncology specialist and an Oncologist in Merced, California. Dr. Abedi is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosenberg's expertise for a condition
ConditionClose
View All 23 Advanced Conditions
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile